Version: 2.0.4 (2023-04-14)
Manso T., Kushwaha A., Abdollahi N., Duroux P., Giudicelli V. and Kossida S. Mechanisms of action of monoclonal antibodies in oncology integrated in IMGT/mAb-DB. Front Immunol., 14 (2023). DOI 10.3389/fimmu.2023.1129323
Poiron C., Wu Y., Ginestoux C., Ehrenmann, Duroux P. and Lefranc M.-P.
IMGT/mAb-DB: the IMGT® database for therapeutic monoclonal antibodies.
JOBIM 2010, Paper 13 (2010).
Abstract
Cambon M., Cherouali K., Kushwaha A., Giudicelli V., Duroux P., Kossida S. and Lefranc M.-P.
IMGT/mAb-DB and IMGT/2Dstructure-DB for IMGT standard definition of an antibody: from receptor to amino acid changes.
JOBIM 2018, Poster 201 (2018).
Abstract
IMGT/mAb-DB ID | 793 |
INN | faricimab |
INN Number | 10563 |
INN Prop. List | 118 (2017) |
INN Rec. List | 80 (2018) |
Common name | RO6867461, RG7716, faricimab-svoa |
Proprietary name | VABYSMO™ |
Species | Homo sapiens Humanized |
IMGT receptor type | IG |
Format (legend) | ![]() |
Receptor identification | IgG1 - kappa - lambda with half-IG VL-CH1/VH-CK crossover |
Radiolabelled / Conjugated / Fused | |
IMGT/2Dstructure-DB | 10563 |
IMGT/3Dstructure-DB | |
Specificity target name and species |
VEGFA
(vascular endothelial growth factor A, VEGF-A, VEGF)
[Homo sapiens, Humanized]
ANGPT2 (angiopoietin 2, Ang2) [Homo sapiens, Humanized] bispecific [Homo sapiens, Humanized] |
Development Technology | CrossMAb technology |
Origin clone species | Mus musculus Homo sapiens |
Origin clone name | ; |
Company | Roche, F. Hoffmann-La Roche Ltd. (Basel Switzerland) |
Expression system | |
Application | Therapeutic |
Clinical domain | Ophthalmology |
Mechanism of action | |
Clinical indication | Age-related macular degeneration (AMD), neovascular (wet) |
Development status | Phase M |
Regulatory agency status and year |
|
Company | Roche, F. Hoffmann-La Roche Ltd. (Basel Switzerland) |
Expression system | CHO (Chinese Hamster Ovary) cells |
Application | Therapeutic |
Clinical domain | Immunology; Ophthalmology |
Mechanism of action | |
Clinical indication | Diabetic macular edema |
Development status | Phase M |
Regulatory agency status and year |
|
Clinical trials | 9 studies found, 1 recruiting |
Authority decisions |
|
External links | |
Biosimilars |